Distributed ledger systems for genome traceability

Introduction

Distributed Ledger Technology (DLT) refers to a digital system in which information is recorded, stored, and shared across multiple interconnected computers or network participants. Blockchain is one of the most widely known forms of distributed ledger technology. In biotechnology, distributed ledger systems can be used to maintain secure, transparent, and traceable records of genetic information, biological samples, genome-editing activities, research findings, and the movement of biological materials.

Genome traceability refers to the ability to identify, monitor, verify, and document the origin, processing, modification, storage, transfer, and use of genetic materials. It is particularly important in genomic research, gene therapy, genetically modified organisms, agricultural biotechnology, clinical trials, and pharmaceutical manufacturing.

Traditional genetic data management systems may face problems involving unauthorized modifications, fragmented records, data duplication, lack of transparency, and difficulties in verifying the origin of biological samples. Distributed ledger systems can address some of these challenges by creating tamper-evident records of transactions and providing controlled access to authorized participants.

For example, when a biological sample is collected from a patient for genomic research, a distributed ledger system may record its collection date, consent status, laboratory transfers, sequencing activities, and research permissions. This can improve accountability and help establish whether the sample was handled according to applicable legal and ethical requirements.

In India, distributed ledger systems for genome traceability are connected with the Information Technology Act, 2000, the Digital Personal Data Protection Act, 2023, the Biological Diversity Act, 2002, the Patents Act, 1970, and applicable biomedical research guidelines.

Meaning and functioning of distributed ledger systems

A distributed ledger is a shared digital record maintained across multiple network participants rather than being controlled entirely by one central database administrator.

Its main characteristics include:

Decentralization: Records may be maintained across multiple authorized participants.

Transparency: Authorized participants can verify relevant transactions.

Immutability: Previously recorded information is designed to be difficult to alter without detection.

Cryptographic security: Cryptographic techniques help protect transaction integrity.

Traceability: Historical records can help identify the origin and movement of biological materials.

Smart contracts: Automated rules can execute predefined actions when specified conditions are satisfied.

In genome traceability, these characteristics can support reliable documentation of biological sample management and genomic research activities.

However, blockchain does not automatically guarantee that the original information entered into the system is accurate. Proper verification procedures remain necessary.

Applications of distributed ledger systems in genome traceability

1. Tracking the origin of genetic materials

Distributed ledger systems can record the origin of biological samples, including blood samples, tissue samples, plant genetic materials, and microorganisms.

Information may include sample identification numbers, collection dates, collection institutions, and relevant consent records.

This helps research institutions establish the provenance of genetic materials and reduce disputes concerning unauthorized collection or use.

For example, a research laboratory receiving biological samples from a hospital can verify the recorded transfer history before using them in genomic research.

2. Monitoring genome-editing activities

Genome-editing technologies such as CRISPR-Cas9 create important requirements for scientific documentation.

Distributed ledger systems can record:

Details of authorized research projects.

Dates of genome-editing experiments.

Research approval references.

Relevant sample identification numbers.

Laboratory personnel and institutional responsibilities.

Verification and quality-control records.

These records can improve research accountability and support regulatory inspections.

3. Protection of genomic data integrity

Genomic information is highly sensitive because it may reveal inherited characteristics and information about biological relationships.

Distributed ledgers can support the integrity of genomic research records through cryptographic verification and controlled transaction histories.

Instead of storing complete genomic sequences directly on a blockchain, institutions can store encrypted information or cryptographic hashes that refer to records held in secure databases.

This approach reduces unnecessary exposure of sensitive genetic information.

4. Consent management in genomic research

Informed consent is essential when human biological samples and genetic information are used for research.

A distributed ledger may maintain records of consent decisions, approved research purposes, and authorized changes to consent preferences.

For example, a patient may authorize the use of a biological sample for a particular research project. The system can record the relevant consent reference and subsequent authorized changes.

However, recording consent on a blockchain does not automatically establish that consent was legally valid or ethically adequate. Researchers must still follow applicable consent requirements.

5. Tracking genetically modified organisms

Distributed ledger systems can support the traceability of genetically modified seeds, agricultural products, and biological materials.

They may record information concerning genetic modification, production, laboratory testing, transportation, and distribution.

This can help regulators and supply-chain participants verify the documented history of genetically modified materials.

6. Pharmaceutical and gene therapy traceability

Gene therapy products and other advanced biological medicines require careful documentation throughout manufacturing and distribution.

DLT systems can help track manufacturing batches, quality-control records, storage conditions, and distribution history.

This improves the ability to investigate product defects, identify affected batches, and support product recall procedures.

Legal framework governing genome traceability in India

1. Information Technology Act, 2000

The Information Technology Act, 2000 provides the legal foundation for electronic records, digital authentication, and certain cybersecurity-related activities.

Important provisions include:

Section 3: Provides for authentication of electronic records through digital signatures.

Section 3A: Provides for electronic signatures.

Section 4: Recognizes legal validity of electronic records.

Section 5: Recognizes legal validity of electronic signatures.

Section 43: Provides compensation for specified unauthorized acts involving computer systems.

Section 66: Addresses specified computer-related offences involving dishonest or fraudulent conduct.

These provisions are relevant when distributed ledger systems are used to maintain electronic records of genomic research and biological sample transactions.

2. Digital Personal Data Protection Act, 2023

The DPDP Act, 2023 establishes a legal framework for processing digital personal data in India.

Genomic information linked or reasonably capable of being linked to an individual may constitute personal data.

Organizations using distributed ledger systems must consider applicable requirements concerning lawful processing, notice, consent where required, data security, and individual rights.

An important legal difficulty arises because blockchain records are designed to be difficult to modify or erase, whereas data protection obligations may require correction or erasure in appropriate circumstances.

Therefore, organizations should generally avoid placing identifiable genomic information directly on immutable public blockchains.

3. Biological Diversity Act, 2002

The Biological Diversity Act regulates access to biological resources and associated traditional knowledge.

Genome traceability can help document the origin, transfer, and utilization of biological resources.

For example, a biotechnology company using biological material obtained from a regulated source may maintain records demonstrating the source and relevant access permissions.

However, maintaining blockchain records does not replace statutory approvals or benefit-sharing obligations.

4. Patents Act, 1970

The Patents Act, 1970 provides protection for eligible biotechnology inventions.

Distributed ledger records may help establish research timelines, laboratory documentation, technology transfer histories, and evidence concerning the development of an invention.

However, a blockchain timestamp does not independently establish patent ownership, inventorship, novelty, or entitlement to patent protection.

5. ICMR National Ethical Guidelines, 2017

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 establish ethical standards for research involving human participants.

These guidelines address informed consent, privacy, confidentiality, research integrity, and institutional ethical oversight.

Distributed ledger systems can support documentation of ethical approvals, sample transfers, and consent records, provided their use remains consistent with participant protection requirements.

Legal issues associated with distributed ledger systems

1. Data privacy and confidentiality

Genomic information can reveal highly personal information about individuals and their biological relatives.

If genomic data are recorded on a distributed ledger without appropriate safeguards, unauthorized participants may obtain access to sensitive information.

Organizations must therefore adopt encryption, access restrictions, data minimization, and secure off-chain storage arrangements.

2. Data correction and erasure

One of the main legal challenges is the difficulty of modifying permanently recorded blockchain transactions.

If genomic information is inaccurate or consent is withdrawn, organizations may need to correct or remove the underlying personal data.

A suitable system should allow correction or deletion of identifiable information stored outside the ledger while retaining only legally permissible, non-identifying verification records where appropriate.

3. Ownership of genomic information

Distributed ledger systems may involve patients, hospitals, research institutions, biotechnology companies, and technology providers.

Disputes may arise concerning access rights, intellectual property, control of research data, and commercialization of genetic discoveries.

The legal position must be determined through applicable legislation, contracts, research agreements, and privacy principles.

4. Cross-border transfer of genomic data

International genomic research frequently involves transferring genetic information between research institutions in different countries.

Such transfers may raise questions concerning applicable data protection requirements, research permissions, contractual obligations, and international data governance.

5. Legal admissibility of blockchain records

Distributed ledger records may be used as evidence in disputes concerning sample transfers, research activities, or contractual obligations.

However, their admissibility depends on applicable evidentiary requirements, authenticity, integrity, and proper certification where required.

Important case laws

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017)

The Supreme Court recognized privacy as a fundamental right under Article 21 and other constitutional freedoms.

The judgment emphasized informational privacy, individual autonomy, and protection against unjustified interference with personal information.

Relevance: Genomic information contains highly sensitive personal details. Distributed ledger systems used for genome traceability must protect individual privacy and prevent unauthorized disclosure of genetic information.

2. Shreya Singhal v. Union of India (2015)

The Supreme Court examined the constitutional validity of Section 66A of the Information Technology Act, 2000 and struck it down for violating freedom of speech and expression.

The judgment also examined intermediary liability under Section 79 and the legal framework for blocking online information.

Relevance: Distributed ledger systems operate through digital networks involving multiple participants. Their legal governance must respect constitutional rights and applicable intermediary and information technology regulations.

3. Anvar P.V. v. P.K. Basheer (2014)

The Supreme Court examined the admissibility of electronic records under the Indian Evidence Act, 1872.

The judgment emphasized compliance with the statutory requirements for admitting secondary electronic evidence, particularly the certificate requirement under the then-applicable Section 65B.

Relevance: Blockchain-based genomic records may be submitted as evidence in disputes involving biological sample ownership, research documentation, or unauthorized data modification. Their evidentiary admissibility must comply with applicable electronic evidence requirements.

4. Arjun Panditrao Khotkar v. Kailash Kushanrao Gorantyal (2020)

The Supreme Court clarified the requirements for admitting electronic records under Section 65B of the Indian Evidence Act, 1872.

The Court reaffirmed the importance of the prescribed certificate for secondary electronic evidence, subject to the applicable legal framework.

Relevance: Distributed ledger records used in biotechnology litigation must satisfy evidentiary requirements. Their technical reliability alone does not automatically establish admissibility.

Note: The Bharatiya Sakshya Adhiniyam, 2023 replaced the Indian Evidence Act, 1872 from 1 July 2024. Current electronic evidence questions must therefore be examined under the applicable provisions of the new legislation.

5. National Legal Services Authority v. Union of India (2014)

The Supreme Court recognized the rights of transgender persons and emphasized dignity, equality, and personal autonomy.

Relevance: Genomic databases may contain information connected with biological characteristics and personal identity. The judgment reinforces the importance of dignity, equality, and protection against discriminatory use of sensitive biological information.

Challenges in implementing distributed ledger systems

The adoption of distributed ledger technology in genome traceability faces several practical and legal challenges.

Privacy concerns: Genetic information requires stronger confidentiality protections.

Technical complexity: Blockchain systems require specialized infrastructure and technical expertise.

Data accuracy: Incorrect information entered into a ledger may remain difficult to correct.

Regulatory uncertainty: Existing laws do not provide a comprehensive framework specifically governing blockchain-based genomic traceability.

High implementation costs: Establishing secure distributed systems may require substantial investment.

Interoperability: Hospitals, laboratories, research institutions, and biotechnology companies may use incompatible information systems.

Cross-border compliance: International genomic research may involve multiple legal jurisdictions.

Consent management: Changes in patient consent must be properly reflected in the associated data management system.

Measures for effective legal and technological governance

A legally compliant genome traceability system should incorporate the following safeguards:

Store identifiable genomic information in secure databases rather than directly on public blockchains.

Use cryptographic hashes to verify the integrity of genomic records.

Maintain clear records of biological sample collection and transfers.

Record relevant informed consent and ethical approval references.

Restrict access to authorized healthcare and research professionals.

Establish procedures for correcting or deleting personal information where legally required.

Conduct regular cybersecurity and privacy assessments.

Maintain proper electronic evidence and audit documentation.

Establish contractual responsibilities among hospitals, laboratories, and technology providers.

Ensure compliance with applicable biodiversity, biosafety, and data protection laws.

Conclusion

Distributed ledger systems provide significant opportunities for improving genome traceability, scientific accountability, and transparency in biotechnology. They can help track biological sample origins, document genome-editing activities, manage consent records, verify genomic research documentation, and improve pharmaceutical supply-chain monitoring.

In India, the Information Technology Act, 2000, Digital Personal Data Protection Act, 2023, Biological Diversity Act, 2002, Patents Act, 1970, and ICMR ethical guidelines provide important legal foundations for governing these systems.

Judicial decisions such as K.S. Puttaswamy v. Union of India, Anvar P.V. v. P.K. Basheer, and Arjun Panditrao Khotkar v. Kailash Kushanrao Gorantyal establish important principles concerning privacy, electronic records, and evidentiary reliability.

Ultimately, distributed ledger technology should be implemented as a secure and accountable traceability mechanism rather than an unrestricted repository of genetic information. Combining cryptographic verification, informed consent, data protection, regulatory oversight, and appropriate access controls can strengthen trust in genomic research while protecting individual rights and scientific integrity.